drugset / Trial / NCT06817720
Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase After Failing One Prior Therapy With a Second Generation Tyrosine Kinase Inhibitor or Asciminib
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To learn if olverembatinib can help to control newly diagnosed CML in the chronic phase.
Timeline
- Start
- 2025-10-13
- Primary completion
- 2027-03-07
- Completion
- 2027-03-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olverembatinib | Small molecule | 30 mg | Oral |